Recommendation to pause use of Johnson & Johnson’s Janssen COVID-19 vaccine

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases,
• Description:
  Updated Apr. 16, 2021
  
  On April 13, 2021, CDC and FDA recommended a pause in the use of Johnson & Johnson’s Janssen COVID-19 Vaccine. Of the nearly 7 million doses administered so far in the United States, a small number of cases of a rare and severe type of blood clot have been reported in people after receiving the J&J/Janssen COVID-19 Vaccine. All reports occurred among women between the ages of 18 and 48, and symptoms occurred six to 13 days after vaccination. As of April 13, 2021, no cases have been reported among the more than 180 million people who received the Pfizer-BioNTech or Moderna vaccines.
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Patient Safety Viral Vaccines
• Document Type:
  Webpage
• Name as Subject:
  Janssen COVID-19 vaccine
• Place as Subject:
  United States
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:3dc53f66d902a77d8d9cd476a2d8f465af6aec03856153cbc735079d785faa0e
• Download URL:
  https://stacks.cdc.gov/view/cdc/105233/cdc_105233_DS1.pdf
• File Type:
  [PDF - 162.15 KB ]